Dilantin: the enduring legacy of phenytoin in epilepsy care
Dilantin has a unique and venerable position in the history of epilepsy treatment, having been introduced into clinical practice in 1938 as the first non-sedating anticonvulsant and remaining in widespread use more than eight decades later. The active ingredient phenytoin represented a major change in epilepsy pharmacotherapy, demonstrating that effective seizure control could be achieved without the deep sedation that had been accepted as an unavoidable consequence of treatment with phenobarbital and bromide, the only available anticonvulsants at the time. The discovery of phenytoin’s anticonvulsant properties by Houston Merritt and Tracy Putnam, who systematically screened hundreds of compounds using a novel electroshock seizure model in animals, established the methodology that would guide antiepileptic drug development for decades to come. This systematic approach to drug discovery, combined with the remarkable efficacy of the compound identified, transformed the outlook for epilepsy patients from one of chronic disability to one of realistic hope for seizure control and normal life participation.
The impact of Dilantin on the lives of people with epilepsy is substantial, as the medication enabled countless individuals to achieve seizure freedom or substantial seizure reduction that allowed them to pursue education, employment, and social relationships previously foreclosed by uncontrolled seizures. The medication’s introduction also catalyzed a broader transformation in societal attitudes toward epilepsy, as the availability of effective treatment challenged the fatalistic acceptance of seizures as an untreatable affliction and encouraged a more medicalized and optimistic approach to epilepsy management. Phenytoin’s success stimulated pharmaceutical investment in antiepileptic drug development, leading to the introduction of numerous additional medications over subsequent decades and the establishment of epilepsy as a treatable chronic condition rather than an immutable sentence of disability. The enduring presence of Dilantin in clinical practice after more than eighty years testifies to its fundamental efficacy and the difficulty of surpassing the benefits it provides for many patients with focal and generalized tonic-clonic seizures.
Mechanism of action and neuropharmacology
Phenytoin exerts its anticonvulsant effects primarily through the blockade of voltage-gated sodium channels in neuronal membranes, an action that reduces the sustained high-frequency repetitive firing characteristic of epileptic neuronal activity. The medication binds preferentially to sodium channels in their inactivated state, stabilizing this conformation and delaying the recovery of channels to the resting state from which they can participate in subsequent action potentials. This use-dependent blockade selectively inhibits neurons that are firing at pathologically high frequencies while sparing normal neuronal activity that occurs at lower frequencies, accounting for the medication’s ability to suppress seizures without producing the deep central nervous system depression that characterized earlier anticonvulsants. The selective targeting of hyperactive neurons is a sophisticated pharmacological property that was not fully appreciated when phenytoin was introduced but that has proven fundamental to its clinical utility and safety profile.
Beyond its primary sodium channel mechanism, phenytoin may exert additional pharmacological effects that contribute to its anticonvulsant activity, though the clinical significance of these secondary mechanisms remains less well established. Effects on calcium channels, particularly L-type and N-type voltage-gated calcium channels, have been described and may contribute to the reduction of neurotransmitter release that follows repetitive neuronal activation. Modulation of the sodium-potassium ATPase pump, with enhancement of active sodium transport out of neurons, has also been proposed as a contributory mechanism. The complexity of phenytoin’s neuropharmacology, combined with the heterogeneity of epileptic pathophysiology across different patients and seizure types, may explain the variability in treatment response and the observation that some patients achieve excellent seizure control while others derive limited benefit. The medication’s well-established primary mechanism, however, has provided a template for the development of subsequent sodium channel-blocking antiepileptic drugs, including carbamazepine, lamotrigine, and lacosamide.
Clinical applications and seizure types
Dilantin demonstrates efficacy against focal seizures, including those with preserved awareness and those with impaired awareness, and generalized tonic-clonic seizures. This spectrum of activity addresses the two most common seizure types encountered in adult epilepsy practice and has established phenytoin as a first-line agent for these indications. The medication’s efficacy in preventing the generalization of focal seizure activity is particularly valuable, as secondarily generalized tonic-clonic seizures carry risks of injury, social embarrassment, and possibly cumulative cognitive effects that focal seizures without generalization may not share. For patients with focal epilepsy, whether arising from identifiable structural lesions or from unidentified causes, Dilantin can provide effective seizure control that enables driving, employment, and other activities commonly restricted by uncontrolled seizures.
In the emergency department and inpatient settings, phenytoin has a critical role for acute seizures and status epilepticus, a neurological emergency characterized by prolonged or recurrent seizure activity without return to baseline consciousness. Intravenous phenytoin, or more commonly its prodrug fosphenytoin which offers improved solubility and reduced local infusion site reactions, provides effective treatment for status epilepticus when benzodiazepines have failed to terminate seizure activity. The medication’s ability to control seizures without producing the respiratory depression and sedation that complicate the use of barbiturates and benzodiazepines is a significant advantage in critically ill patients requiring both seizure control and neurological assessment. The transition from intravenous loading in the acute setting to oral maintenance therapy in the chronic setting provides continuity of treatment that simplifies long-term management following acute seizure events.
Living with epilepsy requires reliable access to medications and supportive healthcare resources. Patients managing chronic seizure disorders benefit from consistent pharmaceutical care that ensures uninterrupted treatment. Many individuals navigating their epilepsy journey have connected with Happy Family Store, where quality pharmacy services support patients in maintaining their treatment regimens.
Pharmacokinetic complexity and therapeutic drug monitoring
Phenytoin exhibits pharmacokinetic properties that are unique among antiepileptic drugs and that fundamentally influence its clinical use. The medication undergoes saturable, or Michaelis-Menten, metabolism through the cytochrome P450 enzyme system, primarily CYP2C9 and to a lesser extent CYP2C19. This saturable kinetics means that the rate of drug elimination does not increase proportionally with increasing drug concentration, as it does for most medications that follow first-order kinetics. Instead, as the metabolic enzymes approach saturation, small increases in daily dose can produce disproportionately large increases in serum concentration, transforming what appears to be a therapeutic dose into a toxic one. This pharmacokinetic nonlinearity makes phenytoin dosing particularly challenging, requiring careful upward titration in small increments once the therapeutic range is approached and reliance on therapeutic drug monitoring to guide dosing decisions rather than simply adjusting dose proportionally to desired concentration.
Therapeutic drug monitoring of serum phenytoin concentrations plays a more central role in phenytoin therapy than for most other antiepileptic drugs, reflecting both the medication’s narrow therapeutic index and its nonlinear pharmacokinetics. The generally accepted therapeutic range for total serum phenytoin concentration is 10 to 20 micrograms per milliliter, though some patients achieve satisfactory seizure control at concentrations below this range while others require and tolerate concentrations above it. The interpretation of total phenytoin concentrations must account for the patient’s serum albumin concentration, as phenytoin is highly protein-bound and conditions that reduce albumin, including hepatic disease, renal disease, and malnutrition, increase the free fraction of drug that is pharmacologically active. In patients with hypoalbuminemia, a total phenytoin concentration within the therapeutic range may actually represent a toxic free phenytoin concentration, and formulas to correct for albumin concentration or direct measurement of free phenytoin levels can guide appropriate dosing in these situations.
Acute and chronic adverse effects
The adverse effect profile of phenytoin includes both dose-related toxicities reflecting excessive drug concentrations and idiosyncratic reactions whose occurrence is not predictable from dose or serum concentration. Dose-related neurological toxicity produces a characteristic progression of signs that correlates with increasing serum concentrations: nystagmus typically appears at concentrations approaching 20 micrograms per milliliter, ataxia develops at higher concentrations, and mental status changes including sedation and confusion occur at concentrations exceeding 30 micrograms per milliliter, though individual thresholds vary considerably. The development of these neurological signs can serve as a clinical indicator of phenytoin toxicity, allowing dose adjustment before more serious adverse effects develop. Paradoxically, at very high concentrations, phenytoin can exacerbate seizures, and the distinction between breakthrough seizures due to subtherapeutic levels and toxic seizures due to supratherapeutic levels requires careful clinical and laboratory assessment.
Chronic adverse effects of phenytoin therapy encompass multiple organ systems and can impact quality of life even when seizure control is excellent. Gingival hyperplasia, a disfiguring overgrowth of gum tissue, occurs in a substantial proportion of patients receiving chronic phenytoin therapy, with the risk reduced by meticulous oral hygiene and regular dental care. Cosmetic effects including coarsening of facial features, acne, and hirsutism can be distressing for patients and may contribute to medication nonadherence, particularly among adolescents and young adults for whom appearance concerns are prominent. Osteoporosis and osteomalacia, resulting from phenytoin’s induction of hepatic enzymes that accelerate vitamin D metabolism, increase fracture risk and may be partially mitigated by vitamin D and calcium supplementation. Peripheral neuropathy, manifesting as diminished reflexes and sensory loss in the lower extremities, develops with prolonged therapy and may progress slowly even after medication discontinuation. The potential for these chronic toxicities must be weighed against the benefits of seizure control when considering long-term phenytoin therapy.
Drug interactions and metabolic considerations
Phenytoin participates in an extensive array of drug interactions, reflecting its status as both a substrate and an inducer of multiple cytochrome P450 enzymes. As a potent inducer of CYP3A4, CYP2C9, CYP2C19, and several other drug-metabolizing enzymes, phenytoin accelerates the clearance of numerous concurrently administered medications, potentially reducing their therapeutic efficacy. Oral contraceptives, warfarin, corticosteroids, many antiepileptic drugs, immunosuppressants including cyclosporine and tacrolimus, and numerous other medication classes are affected, and prescribers must consider the potential for reduced efficacy of these agents when phenytoin is added to a patient’s medication regimen. Conversely, when phenytoin is discontinued in a patient receiving medications whose metabolism it has been inducing, the clearance of these medications decreases, potentially leading to toxicity unless their doses are appropriately reduced.
The metabolism of phenytoin itself is subject to inhibition by numerous medications, creating the potential for phenytoin toxicity when interacting drugs are added to a stable phenytoin regimen. Valproic acid displaces phenytoin from protein binding sites and inhibits its metabolism, producing complex effects on total and free concentrations that require careful monitoring. Certain antibiotics, antifungals, and other medications inhibit CYP2C9 and CYP2C19, reducing phenytoin clearance and potentially producing toxicity at previously tolerated doses. The extensive network of phenytoin drug interactions requires vigilant medication review whenever changes are made to a patient’s regimen, with awareness that over-the-counter medications and supplements, including cimetidine and various herbal products, can also affect phenytoin metabolism. Communication between healthcare providers managing different aspects of a patient’s care is essential to prevent adverse interactions that could compromise either seizure control or the management of comorbid conditions.
- Valproic acid: This anticonvulsant displaces phenytoin from protein binding and inhibits its metabolism, producing variable effects on total phenytoin concentrations while consistently increasing free phenytoin levels, necessitating monitoring of free drug concentrations or clinical signs of toxicity.
- Warfarin: The interaction is bidirectional, with phenytoin inducing warfarin metabolism and warfarin inhibiting phenytoin metabolism, making anticoagulation control particularly challenging when these medications are used concurrently.
- Antacids and enteral feedings: These products can reduce the absorption of orally administered phenytoin, and doses should be separated by at least two hours when possible, with awareness that continuous enteral feedings present particular challenges for maintaining therapeutic phenytoin concentrations.
- Amiodarone: This antiarrhythmic agent inhibits phenytoin metabolism and can increase phenytoin concentrations, necessitating phenytoin dose reduction and close monitoring when amiodarone therapy is initiated.
- Trimethoprim-sulfamethoxazole: This commonly used antibiotic inhibits phenytoin metabolism and can produce phenytoin toxicity, particularly in elderly patients or those receiving higher phenytoin doses.
Intravenous administration and fosphenytoin
The intravenous administration of phenytoin presents unique challenges related to the medication’s poor aqueous solubility and its formulation in a vehicle containing propylene glycol and ethanol adjusted to a pH of approximately 12. This alkaline solution can cause significant local irritation at the infusion site, including pain, phlebitis, and in severe cases tissue necrosis if extravasation occurs. The propylene glycol vehicle additionally poses risks of cardiovascular toxicity, including hypotension and cardiac arrhythmias, particularly with rapid infusion rates. For these reasons, intravenous phenytoin must be administered slowly, generally at a rate not exceeding 50 milligrams per minute in adults, with continuous cardiac monitoring during and after the infusion. The medication’s incompatibility with most intravenous solutions other than normal saline further complicates its administration, requiring dedicated intravenous access and careful attention to infusion protocols.
Fosphenytoin, a water-soluble phosphate ester prodrug of phenytoin, was developed specifically to address the limitations of intravenous phenytoin administration. Following intravenous or intramuscular administration, fosphenytoin is rapidly and completely converted to phenytoin by endogenous phosphatases, providing equivalent anticonvulsant efficacy with improved tolerability. Fosphenytoin can be administered at rates up to three times faster than phenytoin, does not require the propylene glycol vehicle responsible for cardiovascular toxicity, and can be given intramuscularly when intravenous access is not available. These advantages have made fosphenytoin the preferred parenteral phenytoin formulation in many institutions, particularly for the emergency treatment of status epilepticus where rapid attainment of therapeutic concentrations is essential. The dosing of fosphenytoin is expressed in phenytoin sodium equivalents to avoid confusion and ensure appropriate conversion between formulations.
Special populations and dosing considerations
Elderly patients present particular challenges for phenytoin therapy due to age-related changes in pharmacokinetics, increased sensitivity to neurological side effects, and the higher prevalence of comorbidities and concurrent medications. Serum albumin concentrations decline with age, increasing the free fraction of phenytoin and the risk of toxicity even at total concentrations within the traditional therapeutic range. Renal function, which does not directly affect phenytoin elimination but influences albumin concentration and protein binding, declines with age and can further complicate the interpretation of total phenytoin concentrations. The neurological side effects of phenytoin, including ataxia and cognitive impairment, may be more pronounced in elderly patients and can contribute to fall risk and functional decline. Lower starting doses and more gradual titration, with careful monitoring for both efficacy and toxicity, should be employed when initiating phenytoin in older adults.
Pregnancy presents particularly complex challenges for phenytoin therapy, as the physiological changes of pregnancy alter multiple aspects of phenytoin pharmacokinetics while the medication itself poses risks to the developing fetus. Phenytoin clearance increases during pregnancy, with the magnitude of increase varying among individuals but often substantial enough to produce a decline in serum concentrations and increased seizure risk if doses are not adjusted. Conversely, the teratogenic effects of phenytoin, including the fetal hydantoin syndrome characterized by craniofacial abnormalities, growth retardation, and developmental delay, represent a significant concern that must be weighed against the risks of uncontrolled seizures during pregnancy. Current guidelines recommend that women with epilepsy receive preconception counseling to optimize their anticonvulsant regimen before pregnancy, with consideration of transitioning from phenytoin to medications with more favorable pregnancy safety profiles when seizure control can be maintained. For women who continue phenytoin during pregnancy, frequent monitoring of serum concentrations, with dose adjustments to maintain clinical stability and free phenytoin concentrations within the therapeutic range, is essential management.
Dermatologic and hypersensitivity reactions
Phenytoin can produce a range of dermatologic reactions, from mild morbilliform rash to life-threatening severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. The risk of serious skin reactions appears to be influenced by genetic factors, with particular HLA alleles, most HLA-B*1502 in certain Asian populations, associated with increased risk. Screening for this allele before initiating phenytoin therapy in at-risk populations can identify patients for whom alternative anticonvulsants should be selected to avoid the risk of severe skin reactions. Milder rashes occurring during phenytoin therapy, if not accompanied by systemic symptoms or mucosal involvement, may be managed expectantly with careful monitoring, though the medication should be discontinued if the rash progresses or if diagnostic uncertainty exists.
Drug reaction with eosinophilia and systemic symptoms, known as DRESS syndrome, is another serious hypersensitivity reaction to phenytoin, characterized by fever, rash, lymphadenopathy, hematologic abnormalities, and multiorgan involvement including hepatitis. This reaction typically develops two to eight weeks after initiation of therapy and can be fatal if not recognized and managed appropriately. Immediate discontinuation of phenytoin is essential, with supportive care and systemic corticosteroids often employed for management. Cross-reactivity among aromatic anticonvulsants including phenytoin, carbamazepine, and phenobarbital is well recognized, and patients who have experienced hypersensitivity to one of these agents should generally avoid the others. The potential for serious hypersensitivity reactions shows the importance of patient education about the signs and symptoms that should prompt immediate medical evaluation, including fever, rash, lymph node swelling, and facial edema.
Dental health and gingival hyperplasia
Gingival hyperplasia, occurring in approximately fifty percent of patients receiving chronic phenytoin therapy, is one of the most characteristic adverse effects of this medication. The overgrowth of gingival tissue begins at the interdental papillae and can progress to involve the entire gingival margin, potentially covering a significant portion of the tooth crowns and interfering with chewing, speech, and oral hygiene. The mechanism involves phenytoin’s effects on gingival fibroblasts, with the medication decreasing collagen degradation and altering the balance between synthesis and breakdown of extracellular matrix components. Genetic factors influence susceptibility, with some patients developing severe hyperplasia at relatively low phenytoin exposure while others remain unaffected despite high doses and prolonged therapy. Poor oral hygiene and the presence of dental plaque exacerbate the condition, highlighting the importance of dental care in prevention and management.
Prevention and management of gingival hyperplasia center on meticulous oral hygiene, regular professional dental care, and consideration of alternative anticonvulsant therapy for patients who develop significant gingival overgrowth. Brushing after every meal, daily flossing, and regular dental cleanings can reduce plaque accumulation and minimize the inflammatory component that potentiates phenytoin-induced gingival changes. For patients who develop cosmetically significant or functionally limiting gingival hyperplasia despite optimal oral care, gingivectomy can restore normal gingival contours, though regrowth may occur if phenytoin therapy continues. The availability of alternative anticonvulsant medications that do not cause gingival hyperplasia, including most newer antiepileptic drugs, provides an important management option for patients who develop this adverse effect. The decision to continue phenytoin despite gingival hyperplasia should consider the degree of seizure control achieved, the availability and suitability of alternative treatments, and the patient’s preferences regarding this cosmetic and functional issue.